There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oculis Holding (OCS – Research Report), Day One Biopharmaceuticals (DAWN – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
Oculis Holding (OCS)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Oculis Holding, with a price target of $28.00. The company’s shares closed last Tuesday at $11.97.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Oculis Holding is a Strong Buy with an average price target of $27.00.
See Insiders’ Hot Stocks on TipRanks >>
Day One Biopharmaceuticals (DAWN)
In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Day One Biopharmaceuticals, with a price target of $50.00. The company’s shares closed last Tuesday at $16.64, close to its 52-week high of $17.85.
According to TipRanks.com, Maldonado is a 5-star analyst with an average return of
Currently, the analyst consensus on Day One Biopharmaceuticals is a Moderate Buy with an average price target of $35.67, a 128.9% upside from current levels. In a report issued on April 16, Capital One Financial also maintained a Buy rating on the stock with a $40.00 price target.
Neurocrine (NBIX)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine, with a price target of $150.00. The company’s shares closed last Tuesday at $140.09, close to its 52-week high of $148.37.
According to TipRanks.com, Fein is a 4-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $153.81, a 9.1% upside from current levels. In a report issued on April 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $165.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OCS:
- Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
- Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
- Oculis announces listing on Nasdaq Iceland Main Market
- Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
- Oculis names Dr. Snehal Shah as President of Research & Development
